Arkolith/Insider Trading/TSHA/Form 4

Nagendran Sukumar

President and Head of R&D, DirectorTaysha Gene Therapies, Inc. (TSHA) · full profile →Form 4 · filed Dec 1, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.7M
Net Open-Market Flow
-$1.7M
Transactions
8
5 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 1, 2025Sell(S)260K$4.51$1.2M1.0M
Dec 1, 2025Option exercise(M)260K$1.71$445K1.3M
Nov 28, 2025Option exercise(M)70K$0.70$49K1.1M
Nov 28, 2025Sell(S)110K$4.75$523K1.0M
Nov 28, 2025Option exercise(M)40K$1.71$68K1.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 1, 2025Option exercise(M)260K—$0564K
Nov 28, 2025Option exercise(M)70K—$0223K
Nov 28, 2025Option exercise(M)40K—$0824K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001665124-25-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML